Merck KGaA

Clinical research activity is centered on solid tumors, with attention to ongoing treatment needs in participants receiving avelumab within continued oncology care.

• Oncology
• Solid tumor malignancies
• Immune checkpoint therapy

The sponsor’s interest in this area reflects a focus on cancer treatment settings where sustained therapeutic management and long-term safety observation are clinically important.